Reviewing the thoroughness of human safety testing for succinate dehydrogenase inhibitors: fluopyram as a case study - Takeaways - MDSpire

Reviewing the thoroughness of human safety testing for succinate dehydrogenase inhibitors: fluopyram as a case study

  • By

  • Kim Z. Travis

  • Rémi Bars

  • Helen Tinwell

  • February 13, 2026

  • 0 min

Share

  • 1

    Fungal pathogens cause up to 30% crop losses globally, making fungicides essential for disease control in agriculture.

  • 2

    Fluopyram, a novel SDH inhibitor, was developed by Bayer Crop Science for its efficacy against fungi and nematodes.

  • 3

    Human safety assessments for SDH inhibitors like fluopyram have been criticized for lacking thoroughness and completeness.

  • 4

    Regulatory authorities require extensive safety studies, including nearly 3000 for fluopyram, to ensure human and environmental safety.

  • 5

    The paper aims to clarify the human safety studies conducted for fluopyram and address concerns about potential SDH inhibition toxicities.

Original Source(s)

Reviewing the thoroughness of human safety testing for succinate dehydrogenase inhibitors: fluopyram as a case study

  • by Kim Z. Travis, Rémi Bars, Helen Tinwell

  • February 13, 2026

Related Content

Future landscapes of women’s hormone-sensitive cancers: unraveling global trends, age stratification, and regional inequities (1990–2035)

MIT president: Why so many optimistic scientists are losing heart

TEASE Program Builds Case for Gildeuretinol in Stargardt

Philip J. Ferrone, MD, FASRS, reviewed data on gildeuretinol and discussed the ongoing NORTHSTAR pivotal trial at Retina World Congress.